Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The largest prospective warfarin-treated cohort supports genetic forecasting.

Blood - 22 Jan 2009

Wadelius Mia, Chen Leslie Y, Lindh Jonatan D, Eriksson Niclas, Ghori Mohammed J R, Bumpstead Suzannah, Holm Lennart, McGinnis Ralph, Rane Anders, Deloukas Panos

Abstract excerpt

Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate genes in 1496 Swedish patients starting warfarin treatment, and tested for association with response. CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Hemorrhage

Share to Pharmacogenetics

Share to Survival Rate

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 18574025
DOI: 10.1182/blood-2008-04-149070
PMCID: PMC2630264

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The largest prospective warfarin-treated cohort supports genetic forecasting.PMID 18574025Read ↗

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.Semantic proximity Read ↗

Pharmacogenetics in warfarin therapySemantic proximity Read ↗

A multi-factorial analysis of response to warfarin in a UK prospective cohort.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Semantic proximity Read ↗

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.